4,810 Shares in Inspire Medical Systems, Inc. (NYSE:INSP) Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 4,810 shares of the company's stock, valued at approximately $766,000.

Several other institutional investors and hedge funds have also made changes to their positions in INSP. Dragoneer Investment Group LLC purchased a new stake in Inspire Medical Systems during the fourth quarter worth approximately $161,486,000. Congress Asset Management Co. lifted its position in shares of Inspire Medical Systems by 3,943.6% during the 1st quarter. Congress Asset Management Co. now owns 307,555 shares of the company's stock worth $48,987,000 after buying an additional 299,949 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Inspire Medical Systems by 1,775.3% in the 4th quarter. Marshall Wace LLP now owns 277,131 shares of the company's stock valued at $51,375,000 after buying an additional 262,353 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at $47,604,000. Finally, Jacobs Levy Equity Management Inc. grew its position in shares of Inspire Medical Systems by 869.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 210,160 shares of the company's stock valued at $38,959,000 after buying an additional 188,492 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Down 0.1%

Shares of NYSE INSP traded down $0.19 during mid-day trading on Wednesday, hitting $130.62. 479,565 shares of the company were exchanged, compared to its average volume of 550,885. The stock has a 50 day simple moving average of $143.22 and a 200-day simple moving average of $164.59. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $225.00. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 60.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.25.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 7.92% and a return on equity of 10.00%. The firm had revenue of $201.32 million during the quarter, compared to the consensus estimate of $194.89 million. During the same quarter last year, the firm earned ($0.34) earnings per share. The firm's revenue was up 22.7% compared to the same quarter last year. Analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INSP has been the subject of a number of research reports. Stifel Nicolaus reduced their price target on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Morgan Stanley cut their target price on Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. KeyCorp decreased their target price on Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. JPMorgan Chase & Co. dropped their price target on Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Finally, Royal Bank Of Canada cut their price target on Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 15th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $211.91.

Insider Activity at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 360 shares of the firm's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the completion of the sale, the director owned 24,046 shares in the company, valued at $3,847,360. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 2.30% of the company's stock.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.